Granted Patent B2

US 12,207,902 · App. 17/693,690 · Granted Jan 28, 2025

Inventors: Parsin Haji Reza (Waterloo, CA); Roger Zemp (Waterloo, CA)

Assignee: ILLUMISONICS INC.

A61B5/0095G01N21/1702G01N21/1717G01N2021/1706G01N2021/1725G01N2201/06113G01N2201/08G01N2201/0846

Abstract

Claims (145)

1. A system for visualizing details in a sample, comprising:

one or more light sources configured to generate:

a first beam configured to generate signals in a sample at a first location, and

a second beam incident on the sample at the first location, a portion of the second beam returning from the sample that is indicative of the generated signals;

an optical system configured to focus at least one of the first beam or the second beam below a surface of the sample; and

a detector configured to detect the returning portion of the second beam,

wherein the system does not contact the sample.

2. The system of claim 1 , wherein the one or more light sources include one or more lasers.

3. The system of claim 1 , wherein the first beam is pulsed or intensity-modulated.

4. The system of claim 1 , wherein the second beam is pulsed, intensity-modulated, or continuous.

5. The system of claim 1 , wherein the generated signals are ultrasonic and/or photoacoustic signals.

6. The system of claim 1 , wherein the generated signals are thermal signals.

7. The system of claim 1 , wherein the optical system is configured to:

focus the first beam at a first focal point that is below the surface of the sample, and

focus the second beam at a second focal point that is below the surface of the sample.

8. The system of claim 1 , further comprising a processor configured to calculate an image based on the returned portion of the second beam.

9. The system of claim 8 , wherein the processor is configured to analyze the generated signals as a function of time.

10. The system of claim 8 , wherein the processor is configured to determine a maximum amplitude for the generated signals.

11. The system of claim 8 , wherein the image is a maximum amplitude projection (MAP) image.

12. The system of claim 1 , wherein the system is used in one or more of the following applications:

imaging of blood oxygen saturation;

imaging of tumor hypoxia;

imaging of wound healing, burn diagnostics, or surgery;

imaging of microcirculation;

blood oxygenation parameter imaging;

estimating blood flow in vessels flowing into and out of a region of tissue;

imaging of molecularly-specific targets;

imaging angiogenesis for pre-clinical tumor models;

clinical imaging of micro- and macro-circulation and pigmented cells;

imaging of the eye;

augmenting or replacing fluorescein angiography;

imaging dermatological lesions;

imaging melanoma;

imaging basal cell carcinoma;

imaging hemangioma;

imaging psoriasis;

imaging eczema;

imaging dermatitis;

imaging Mohs surgery;

imaging to verify tumor margin resections;

imaging peripheral vascular disease;

imaging diabetic and/or pressure ulcers;

burn imaging;

plastic surgery;

microsurgery;

imaging of circulating tumor cells;

imaging melanoma cells;

imaging lymph node angiogenesis;

imaging response to photodynamic therapies;

imaging response to photodynamic therapies having vascular ablative mechanisms;

imaging response to chemotherapeutics;

imaging response to anti-angiogenic drugs;

imaging response to radiotherapy;

estimating oxygen saturation using multi-wavelength photoacoustic excitation;

estimating venous oxygen saturation where pulse oximetry cannot be used;

estimating cerebrovenous oxygen saturation and/or central venous oxygen saturation;

estimating oxygen flux and/or oxygen consumption;

imaging vascular beds and depth of invasion in Barrett's esophagus and/or colorectal cancers;

functional imaging during brain surgery;

assessment of internal bleeding and/or cauterization verification;

imaging perfusion sufficiency of organs and/or organ transplants;

imaging angiogenesis around islet transplants;

imaging of skin-grafts;

imaging of tissue scaffolds and/or biomaterials to evaluate vascularization and/or immune rejection;

imaging to aid microsurgery;

guidance to avoid cutting blood vessels and/or nerves;

imaging of contrast agents in clinical or pre-clinical applications;

identification of sentinel lymph nodes;

non- or minimally-invasive identification of tumors in lymph nodes;

imaging of genetically-encoded reporters, wherein the genetically-encoded reporters include tyrosinase, chromoproteins, and/or fluorescent proteins for pre-clinical or clinical molecular imaging applications;

imaging actively or passively targeted optically absorbing nanoparticles for molecular imaging;

imaging of blood clots; or

staging an age of blood clots.

13. A system, comprising:

one or more light sources configured to:

generate signals in the sample at a first location using a first beam, the first beam being focused below a surface of a sample, and

interrogate the sample with a second beam directed toward the first location of the sample, the second beam being focused below the surface of the sample; and

a detector configured to detect a portion of the second beam returning from the sample,

wherein the system does not contact the sample.

14. The system of claim 13 , further comprising a processor configured to form an image based on the returned portion of the second beam.

15. The system of claim 14 , wherein the processor is configured to determine a maximum amplitude of the generated signals and project the maximum amplitude as a pixel to form the image.

16. An endoscopic device including the system of claim 13 .

17. The endoscopic device of claim 16 , including a cable having a first end and a second end, wherein the one or more light sources and the detector are provided at the first end.

18. The system of claim 13 , wherein the system is used in one or more of the following applications:

imaging of blood oxygen saturation;

imaging of tumor hypoxia;

imaging of wound healing, burn diagnostics, or surgery;

imaging of microcirculation;

blood oxygenation parameter imaging;

estimating blood flow in vessels flowing into and out of a region of tissue;

imaging of molecularly-specific targets;

imaging angiogenesis for pre-clinical tumor models;

clinical imaging of micro- and macro-circulation and pigmented cells;

imaging of the eye;

augmenting or replacing fluorescein angiography;

imaging dermatological lesions;

imaging melanoma;

imaging basal cell carcinoma;

imaging hemangioma;

imaging psoriasis;

imaging eczema;

imaging dermatitis;

imaging Mohs surgery;

imaging to verify tumor margin resections;

imaging peripheral vascular disease;

imaging diabetic and/or pressure ulcers;

burn imaging;

plastic surgery;

microsurgery;

imaging of circulating tumor cells;

imaging melanoma cells;

imaging lymph node angiogenesis;

imaging response to photodynamic therapies;

imaging response to photodynamic therapies having vascular ablative mechanisms;

imaging response to chemotherapeutics;

imaging response to anti-angiogenic drugs;

imaging response to radiotherapy;

estimating oxygen saturation using multi-wavelength photoacoustic excitation;

estimating venous oxygen saturation where pulse oximetry cannot be used;

estimating cerebrovenous oxygen saturation and/or central venous oxygen saturation;

estimating oxygen flux and/or oxygen consumption;

imaging vascular beds and depth of invasion in Barrett's esophagus and/or colorectal cancers;

functional imaging during brain surgery;

assessment of internal bleeding and/or cauterization verification;

imaging perfusion sufficiency of organs and/or organ transplants;

imaging angiogenesis around islet transplants;

imaging of skin-grafts;

imaging of tissue scaffolds and/or biomaterials to evaluate vascularization and/or immune rejection;

imaging to aid microsurgery;

guidance to avoid cutting blood vessels and/or nerves;

imaging of contrast agents in clinical or pre-clinical applications;

identification of sentinel lymph nodes;

non- or minimally-invasive identification of tumors in lymph nodes;

imaging of genetically-encoded reporters, wherein the genetically-encoded reporters include tyrosinase, chromoproteins, and/or fluorescent proteins for pre-clinical or clinical molecular imaging applications;

imaging actively or passively targeted optically absorbing nanoparticles for molecular imaging;

imaging of blood clots; or

staging an age of blood clots.

19. A method of visualizing details in a sample, the method comprising the steps of:

receiving, via one or more reflected beams, one or more photoacoustic remote sensing (PARS) signals;

determining a maximum amplitude of the received one or more PARS signals; and

projecting the maximum amplitude as a pixel to form an image visualizing details in a sample,

wherein the method does not use a transducer.

20. The method of claim 19 , wherein the PARS signals are collected by:

generating signals in the sample at an excitation location using an excitation beam of light, the excitation beam being focused below a surface of the sample; and

interrogating the sample with an interrogation beam of light directed toward the excitation location of the sample, the interrogation beam being focused below the surface of the sample, wherein the one or more reflected beams include a portion of the interrogation beam returning from the sample.

Assignments (1)

Continuity (5)

References Cited (69)